

ASX Announcement

6 December 2022

Change in Commitments Test Classification : Removal of requirement to lodge Appendix 4C

Cogstate Limited (ASX:CGS) advises that, following discussions with ASX Limited (ASX), the ASX has exercised its discretion to remove the requirement for Cogstate to lodge Appendix 4C Quarterly Cashflow Reports.

As a result, Cogstate's Appendix 4C Quarterly Cash Flow Report for the quarter ended 30 September 2022, which was lodged with the ASX on 20 October 2022, will be the final Appendix 4C lodged by Cogstate.

Cogstate is still required to lodge preliminary final reports, in the form of Appendix 4E, and half yearly reports, in the form of Appendix 4D, within two months of the end of the relevant accounting period.

Cogstate's next periodic report under Chapter 4 of the ASX Listing Rules will be its half year report for the period ending 31 December 2022 (Appendix 4D), due no later than 28 February 2023.

This announcement was authorised for release by a sub-committee of the Board of Directors of Cogstate Ltd.

About Cogstate

Cogstate Ltd (ASX:CGS) is the neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. The company's clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches, advanced analytics and scientific consulting. For 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world. In the Healthcare market, in August 2019 Cogstate entered into an exclusive licensing agreement with the pharmaceutical company Eisai, under which Eisai will market Cogstate technologies as digital cognitive assessment tools in Japanese markets. In October 2020, Cogstate extended its agreement with Eisai to the Rest of the World. The product, branded as NouKNOW, launched in Japan on 31 March 2020 (nouknow.jp). For more information, please visit www.cogstate.com.

For further information contact:

Brad O'Connor, Chief Executive Officer, boconnor@cogstate.com